The surge in GLP-1 drug development is not merely a trend; it has catalyzed a significant wave of mergers and acquisitions within the biopharmaceutical landscape. As major players like Novo Nordisk and Eli Lilly reap substantial revenues from obesity treatments, they are increasingly focused on identifying the next transformative assets. This article explores five biotech companies poised as attractive acquisition targets, ranging from dedicated GLP-1 developers to those with adjacent therapeutic pipelines that offer diversification into oncology, immunology, and neuroscience.
Viking Therapeutics: A Direct GLP-1 Contender
Viking Therapeutics stands out as a prime candidate for acquisition, thanks to its lead drug candidate, VK2735. This dual GLP-1/GIP receptor agonist is available in both oral and subcutaneous forms. The ongoing VANQUISH Phase 3 trial has already enrolled over 4,500 patients, with VANQUISH-2 set to complete enrollment in the first quarter of 2026. In previous studies, oral VK2735 demonstrated a promising 12.2% reduction in body weight at just 13 weeks. The next phase of trials is scheduled to kick off in Q3 2026.
Current market sentiment indicates a 25.5% implied probability for a Viking acquisition before 2027, highlighting its attractiveness to big pharma. Despite trading at less than $33 per share, significantly below the consensus analyst target of $92.72, the stock is buoyed by 17 Buy ratings and just two Holds. Additionally, Viking has a DACRA pipeline candidate with an Investigational New Drug application filed, adding further appeal for potential acquirers.
Structure Therapeutics: Building a Best-in-Class Franchise
Structure Therapeutics is making strides in developing an oral GLP-1 franchise that could redefine the market. Its lead asset, aleniglipron, delivered impressive results in the Phase 2b ACCESS trial, achieving placebo-adjusted mean weight loss of 11.3% at 120 mg and a remarkable 15.3% at 240 mg over 36 weeks. With higher-dose data expected in early 2026 and a Phase 3 program slated for the second half of 2026, the company is well-positioned for growth.
Despite a 28.9% decline year-to-date, Structure’s stock has surged 178.5% over the past year. Currently priced around $49, it remains well below the $109 consensus analyst target, further solidified by strong recommendations from 15 of the 16 analysts covering the stock. The company’s robust cash position of $1.45 billion also serves to lower the net acquisition cost for interested buyers.
Revolution Medicines: Oncology as a Diversification Strategy
For acquirers focused on building a metabolic and oncology portfolio, Revolution Medicines provides an intriguing opportunity. While not directly involved in GLP-1 therapies, its RAS(ON) inhibitor platform targets pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), making it a valuable asset in precision oncology. With a market cap of $19.3 billion and a stock increase of 175.0% over the past year, the company is gaining significant traction.
A Phase 3 readout for daraxonrasib in second-line metastatic PDAC is anticipated in the first half of 2026. Additionally, zoldonrasib holds FDA Breakthrough Therapy designation for NSCLC, showcasing its potential in treating RAS G12D mutations. The consensus analyst target for Revolution is $133.70, supported by 20 Buy ratings, making it an attractive candidate for large pharma looking to diversify their portfolios.
Vera Therapeutics: A Catalyst in Autoimmune Disease
Vera Therapeutics provides a near-term commercial opportunity in the autoimmune space, particularly for those interested in complementing a metabolic franchise. Its lead candidate, atacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy, achieved a significant 46% reduction in proteinuria at week 36 in the Phase 3 ORIGIN 3 trial. The drug’s potential has been recognized with priority review status from the FDA, and a Biologics License Application (BLA) is set for a decision by July 7, 2026.
Trading near $40, Vera’s stock is positioned against a consensus target of $79, bolstered by 11 Buy ratings. The company’s solid cash reserves of $714.59 million ensure that operations can proceed smoothly through the anticipated launch and beyond, making it an appealing target for larger firms seeking immunology assets.
Alkermes: Merging Commercial Scale with CNS Innovation
Alkermes represents a unique combination of commercial strength and a promising CNS pipeline. Following its acquisition of Avadel Pharmaceuticals for $2.3 billion, Alkermes now boasts multiple successful products, including Vivitrol and Lybalvi. The latter has shown a year-over-year growth of 22.3% in Q4 2025, with revenue projections for 2026 estimated between $1.73 billion and $1.84 billion.
The company’s alixorexton program, which focuses on narcolepsy type 1 and has received FDA Breakthrough Therapy designation, is entering Phase 3 trials. Alkermes’ stock has climbed 26.4% year-to-date, currently trading at $35.36, with a consensus target of $43.71. With 12 Buy ratings and a promising adjusted EBITDA forecast of $370 million to $410 million, Alkermes stands out as a commercially viable mid-cap acquisition target.
Conclusion: A Landscape Rich with Opportunities
The GLP-1 revolution has not only invigorated the biopharma sector but has also sparked a broader M&A cycle that can extend well beyond obesity treatments. Viking Therapeutics and Structure Therapeutics are direct contenders in the GLP-1 space, while Revolution Medicines, Vera Therapeutics, and Alkermes offer diversified opportunities for large pharmaceutical firms. With strong analyst support, pivotal clinical catalysts on the horizon, and valuations appealing to cash-rich buyers, these companies are well-positioned for potential acquisition in a rapidly evolving market.
- Viking Therapeutics leads with a dual GLP-1/GIP receptor agonist.
- Structure Therapeutics is developing an innovative oral GLP-1 franchise.
- Revolution Medicines offers advanced oncology solutions.
- Vera Therapeutics focuses on autoimmune conditions with near-term commercial potential.
- Alkermes brings commercial scale and CNS innovation to the table.
These factors make the biotech landscape ripe for strategic acquisitions.
Read more → 247wallst.com